Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP4OX added to usual care in severe trauma with hemorrhagic shock
2010-023129-39Phase 2Active
- Sponsor
- Sangart
- Start
- Jan 2011
- Modality
- Albumin → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Hemospan in hemorrhagic shock (2 arms), sponsored by Sangart. Primary endpoint: Primary efficacy endpoint. Started Jan 2011; status: active.
02
Drugs
Hemospan
03
Conditions
hemorrhagic shock
Beyond the preview
Go deeper on 2010-023129-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023129-39.